Pill Peddling Doc Convicted; Digital Schizophrenia Therapeutic Cleared; AI Anxiety

Jonathan Decker, MD, of Michigan, was convicted of peddling more than 2 million stimulant pills, including amphetamine-dextroamphetamine salts (Adderall), on the Done ADHD telehealth platform, according to the Department of Justice.

The FDA cleared the prescription digital therapeutic Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care, Click Therapeutics said.

The agency is also soliciting public feedback on ibogaine drug development to help design future early-phase clinical trials.

A national survey revealed stronger support for the civil rights of people with severe physical disabilities compared with those with mental illness or substance use disorder. (JAMA Health Forum)

Anxiety over artificial intelligence (AI) is becoming a prominent topic in therapy sessions. (New York Times)

The U.S. Senate approved bills that would make it easier for airline professionals to get mental health support without sinking their careers. (The Guardian)

Psilocybin use among adults with depression was associated with a higher perceived unmet treatment need in the 2024 National Survey on Drug Use and Health. (Psychological Medicine)

Vanda Pharmaceuticals said its dual melatonin MT1/MT2 receptor agonist, tasimelteon (Hetlioz), met its primary endpoint in a phase III trial for delayed sleep-wake phase disorder.

While about half of Medicaid-enrolled young people with opioid use disorder started addiction treatment, only one in 32 received sustained pharmacotherapy, a study in JAMA Network Open indicated.

A Danish cohort study linked long-term exposure to road traffic noise with an increased risk of depression. (Lancet Regional Health Europe)

Golf legend Phil Mickelson checked himself into a treatment facility to address family trauma and addiction. (NBC News)

Prisons are getting hotter and more inmates are dying from suicide. (AP)